About Helios
Helios is a company based in Tokyo (Japan) founded in 2011. It operates as a HealthTech. Helios has raised $29.17 million across 2 funding rounds from investors including Nikon, European Union and Sumitomo Dainippon Pharma. The company has 65 employees as of December 31, 2024. Helios offers products and services including iPSC Regenerative Medicine, Somatic Stem Cell Regenerative Medicine, and Cancer Immunotherapy (NK Cells). Helios operates in a competitive market with competitors including Kriya Therapeutics, Annexon, Aldeyra, Blue Rock Therapeutics and Nicox, among others.
- Headquarter Tokyo, Japan
- Employees 65 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Healios Kk
-
Annual Revenue
$3.57 M (USD)362.81as on Dec 31, 2024
-
Net Profit
-$27.01 M (USD)-10.78as on Dec 31, 2024
-
EBITDA
-$16.56 M (USD)13.37as on Dec 31, 2024
-
Total Equity Funding
$29.17 M (USD)
in 2 rounds
-
Latest Funding Round
$55.99 K (USD), Grant
Jun 01, 2019
-
Investors
Nikon
& 2 more
-
Employee Count
65
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Helios
Helios is a publicly listed company on the TSE with ticker symbol 4593 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Helios
Helios offers a comprehensive portfolio of products and services, including iPSC Regenerative Medicine, Somatic Stem Cell Regenerative Medicine, and Cancer Immunotherapy (NK Cells).
Innovative therapies are developed using iPSC technology.
Treatments are created using somatic stem cells.
Cancer treatments are developed using NK cells.
Funding Insights of Helios
Helios has successfully raised a total of $29.17M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $55.99 thousand completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Helios
Helios has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Nikon, European Union and Sumitomo Dainippon Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Pharmaceuticals, food ingredients, additives, and veterinary products are manufactured.
|
Locked | Locked | Locked | |
|
Nikon is recognized as a key technology solutions company.
|
Locked | Locked | Locked |
Investor details for Helios
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Helios
Investment portfolio details for Helios
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Helios
Detailed financials for Helios
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Helios Comparisons
Peer comparison for Helios
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Helios
Helios operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, Aldeyra, Blue Rock Therapeutics and Nicox, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Stem cell therapies are developed for cardiovascular and neurological diseases.
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
Detailed competitors of Helios
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Helios
Complete news archive for Helios
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Helios
Helios was founded in 2011 and raised its 1st funding round 2 years after it was founded.
Helios is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.
Helios is a funded company, having raised a total of $29.17M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Helios is 65.
Annual revenue of Helios is $3.57M as on Dec 31, 2024.
Helios is focused on the development of regenerative medicine therapies to expand treatment options for patients worldwide. The company operates in sectors such as iPSC regenerative medicine, somatic stem cell therapies, and cancer immunotherapy using NK cells. Solutions are being researched for conditions like age-related macular degeneration, liver diseases, stroke, and acute respiratory distress syndrome (ARDS). Innovative strategies are employed to deliver new treatment methods and hope to patients globally.
Helios's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Helios offers iPSC Regenerative Medicine, Somatic Stem Cell Regenerative Medicine, and Cancer Immunotherapy (NK Cells).
Yes, Helios is publicly traded on TSE under the ticker symbol 4593.
Helios has 3 investors. Key investors include Nikon, European Union, and Sumitomo Dainippon Pharma.
The ticker symbol of Helios is 4593 on TSE.